| Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ... J Clin Oncol 23 (34), 8580-7, 2005 | 1600 | 2005 |
| Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small … H Linardou, IJ Dahabreh, D Kanaloupiti, F Siannis, D Bafaloukos, ... The lancet oncology 9 (10), 962-972, 2008 | 946 | 2008 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 433 | 2021 |
| Thalidomide and dexamethasone combination for refractory multiple myeloma MA Dimopoulos, K Zervas, G Kouvatseas, E Galani, V Grigoraki, ... Annals of Oncology 12 (7), 991-995, 2001 | 419 | 2001 |
| Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies S Murray, E Briasoulis, H Linardou, D Bafaloukos, C Papadimitriou Cancer treatment reviews 38 (7), 890-903, 2012 | 291 | 2012 |
| Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications A Soultati, G Mountzios, C Avgerinou, G Papaxoinis, D Pectasides, ... Cancer treatment reviews 38 (5), 473-483, 2012 | 233 | 2012 |
| Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study … A Bamias, G Aravantinos, C Deliveliotis, D Bafaloukos, C Kalofonos, ... Journal of Clinical Oncology 22 (2), 220-228, 2004 | 218 | 2004 |
| Trastuzumab administration during pregnancy: a systematic review and meta-analysis F Zagouri, TN Sergentanis, D Chrysikos, CA Papadimitriou, ... Breast cancer research and treatment 137, 349-357, 2013 | 193 | 2013 |
| Hormonal Therapy with Letrozole for Relapsed Epithelial Ovarian CancerLong-Term Results of a Phase II Study CA Papadimitriou, S Markaki, J Siapkaras, G Vlachos, E Efstathiou, ... Oncology 66 (2), 112-117, 2004 | 159 | 2004 |
| Front-line treatment of advanced non–small-cell lung cancer with docetaxel and gemcitabine: A multicenter phase II trial V Georgoulias, C Kouroussis, N Androulakis, S Kakolyris, MA Dimopoulos, ... Journal of clinical oncology 17 (3), 914-914, 1999 | 158 | 1999 |
| Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix CA Papadimitriou, K Sarris, LA Moulopoulos, G Fountzilas, ... Journal of clinical oncology 17 (3), 761-761, 1999 | 132 | 1999 |
| Granulosa cell tumor of the ovary: tumor review GV Koukourakis, VE Kouloulias, MJ Koukourakis, GA Zacharias, ... Integrative cancer therapies 7 (3), 204-215, 2008 | 131 | 2008 |
| Outcomes after adjuvant chemotherapy in the treatment of high‐risk urothelial carcinoma of the upper urinary tract (UUT‐UC) Results from a large multicenter collaborative study M Vassilakopoulou, T de la Motte Rouge, P Colin, A Ouzzane, D Khayat, ... Cancer 117 (24), 5500-5508, 2011 | 130 | 2011 |
| Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative … F Fostira, M Tsitlaidou, C Papadimitriou, M Pertesi, E Timotheadou, ... Breast cancer research and treatment 134, 353-362, 2012 | 125 | 2012 |
| Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized … G Fountzilas, D Skarlos, U Dafni, H Gogas, E Briasoulis, D Pectasides, ... Annals of oncology 16 (11), 1762-1771, 2005 | 121 | 2005 |
| Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study MA Dimopoulos, CA Papadimitriou, V Georgoulias, LA Moulopoulos, ... Gynecologic oncology 78 (1), 52-57, 2000 | 115 | 2000 |
| Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study N Androulakis, C Kourousis, MA Dimopoulos, G Samelis, S Kakolyris, ... Journal of clinical oncology 17 (6), 1779-1779, 1999 | 110 | 1999 |
| Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article GV Koukourakis, V Kouloulias, G Zacharias, C Papadimitriou, ... Molecules 14 (4), 1561-1577, 2009 | 104 | 2009 |
| Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized … P Kosmidis, N Mylonakis, D Skarlos, E Samantas, M Dimopoulos, ... Annals of oncology 11 (7), 799-805, 2000 | 97 | 2000 |
| The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality M Papadimitriou, G Mountzios, CA Papadimitriou Cancer treatment reviews 67, 34-44, 2018 | 94 | 2018 |
